Published in Mol Cancer on March 23, 2012
Development of covalent inhibitors that can overcome resistance to first-generation FGFR kinase inhibitors. Proc Natl Acad Sci U S A (2014) 0.99
βKlotho suppresses tumor growth in hepatocellular carcinoma by regulating Akt/GSK-3β/cyclin D1 signaling pathway. PLoS One (2013) 0.87
Individualized medicine enabled by genomics in Saudi Arabia. BMC Med Genomics (2015) 0.87
Regulation of amphiregulin gene expression by β-catenin signaling in human hepatocellular carcinoma cells: a novel crosstalk between FGF19 and the EGFR system. PLoS One (2012) 0.85
Is fibroblast growth factor receptor 4 a suitable target of cancer therapy? Curr Pharm Des (2014) 0.80
Klotho: a novel biomarker for cancer. J Cancer Res Clin Oncol (2014) 0.80
Novel combination of sorafenib and celecoxib provides synergistic anti-proliferative and pro-apoptotic effects in human liver cancer cells. PLoS One (2013) 0.79
Fibroblast growth factor family as a potential target in the treatment of hepatocellular carcinoma. J Hepatocell Carcinoma (2014) 0.75
2-Aminopyrimidine Derivatives as New Selective Fibroblast Growth Factor Receptor 4 (FGFR4) Inhibitors. ACS Med Chem Lett (2017) 0.75
Targeting FGF19/FGFR4 Pathway: A Novel Therapeutic Strategy for Hepatocellular Carcinoma. Diseases (2015) 0.75
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer (2010) 90.16
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab (2005) 9.14
Phosphorylation of c-jun mediated by MAP kinases. Nature (1991) 8.07
PI3K: downstream AKTion blocks apoptosis. Cell (1997) 7.73
Gene expression patterns in human liver cancers. Mol Biol Cell (2002) 6.93
Molecular targeted therapies in hepatocellular carcinoma. Hepatology (2008) 6.16
Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology (2007) 5.75
Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med (2003) 5.45
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 4.42
Human hepatic stem cells from fetal and postnatal donors. J Exp Med (2007) 4.15
BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 4.00
CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene (2007) 3.96
Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J Biol Chem (2000) 3.37
Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J Clin Invest (2005) 2.62
Cancer stem/progenitor cells are highly enriched in CD133+CD44+ population in hepatocellular carcinoma. Int J Cancer (2010) 2.54
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis (2005) 2.18
The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res (2010) 2.12
A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am J Pathol (2002) 2.02
Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele. Cancer Res (2002) 1.95
Liver-specific activities of FGF19 require Klotho beta. J Biol Chem (2007) 1.90
Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol (1997) 1.85
Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol (2007) 1.71
FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. PLoS One (2011) 1.35
Specificity for fibroblast growth factors determined by heparan sulfate in a binary complex with the receptor kinase. J Biol Chem (1999) 1.34
SK HEP-1: a human cell line of endothelial origin. In Vitro Cell Dev Biol (1992) 1.30
FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation. J Biol Chem (2009) 1.26
Cellular aspects of alpha-fetoprotein reexpression in tumors. Semin Cancer Biol (1999) 1.22
Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma. Int J Cancer (2004) 1.20
Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis. Mol Carcinog (2006) 1.06
Resident hepatocyte fibroblast growth factor receptor 4 limits hepatocarcinogenesis. Mol Carcinog (2009) 1.05
Hepatic progenitor cells, stem cells, and AFP expression in models of liver injury. Int J Exp Pathol (2006) 1.01
Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation. J Biol Chem (2010) 0.94
Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med (2003) 5.97
Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int (2010) 5.02
Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med (2003) 4.12
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology (2006) 3.80
Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med (2005) 3.46
Management of chronic hepatitis C: consensus guidelines. Can J Gastroenterol (2007) 2.06
Serum autoantibodies as biomarkers for early cancer detection. FEBS J (2009) 1.94
Management of chronic hepatitis B: consensus guidelines. Can J Gastroenterol (2007) 1.78
Treatment of chronic hepatitis B virus infection in resource-constrained settings: expert panel consensus. Liver Int (2011) 1.75
Profile of tumor antigen-specific CD8 T cells in patients with hepatitis B virus-related hepatocellular carcinoma. Gastroenterology (2009) 1.70
Intragastric balloon significantly improves nonalcoholic fatty liver disease activity score in obese patients with nonalcoholic steatohepatitis: a pilot study. Gastrointest Endosc (2012) 1.55
A novel severe acute respiratory syndrome coronavirus protein, U274, is transported to the cell surface and undergoes endocytosis. J Virol (2004) 1.53
PCBP1 suppresses the translation of metastasis-associated PRL-3 phosphatase. Cancer Cell (2010) 1.48
Cumulative viral evolutionary changes in chronic hepatitis B virus infection precedes hepatitis B e antigen seroconversion. Gut (2012) 1.47
Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol (2010) 1.38
Health-related quality of life in chronic hepatitis B patients. Hepatology (2008) 1.38
A longitudinal analysis of innate and adaptive immune profile during hepatic flares in chronic hepatitis B. J Hepatol (2010) 1.35
Profiles of antibody responses against severe acute respiratory syndrome coronavirus recombinant proteins and their potential use as diagnostic markers. Clin Diagn Lab Immunol (2004) 1.34
A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology (2004) 1.34
ERCP in patients with periampullary diverticulum. Hepatogastroenterology (2003) 1.34
Cellular RNA helicase p68 relocalization and interaction with the hepatitis C virus (HCV) NS5B protein and the potential role of p68 in HCV RNA replication. J Virol (2004) 1.32
Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int (2006) 1.30
Overexpression of 7a, a protein specifically encoded by the severe acute respiratory syndrome coronavirus, induces apoptosis via a caspase-dependent pathway. J Virol (2004) 1.24
Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol (2008) 1.21
The severe acute respiratory syndrome coronavirus 3a is a novel structural protein. Biochem Biophys Res Commun (2005) 1.21
Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. Biochem Biophys Res Commun (2009) 1.20
Carbon nanotubes for delivery of small molecule drugs. Adv Drug Deliv Rev (2013) 1.18
The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol (2007) 1.16
Magnetic resonance elastography for the detection and staging of liver fibrosis in chronic hepatitis B. Eur Radiol (2013) 1.15
Mesenchymal stem cell-derived exosomes promote hepatic regeneration in drug-induced liver injury models. Stem Cell Res Ther (2014) 1.15
CDK1 inhibitors antagonize the immediate apoptosis triggered by spindle disruption but promote apoptosis following the subsequent rereplication and abnormal mitosis. Cell Cycle (2008) 1.12
Comparing the antibody responses against recombinant hemagglutinin proteins of avian influenza A (H5N1) virus expressed in insect cells and bacteria. J Med Virol (2008) 1.10
Expression of a full-length hepatitis C virus cDNA up-regulates the expression of CC chemokines MCP-1 and RANTES. Virology (2002) 1.10
Practical difficulties in the management of hepatitis B in the Asia-Pacific region. J Gastroenterol Hepatol (2004) 1.09
Bioactivation and hepatotoxicity of nitroaromatic drugs. Curr Drug Metab (2006) 1.07
Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. Mol Pharmacol (2010) 1.05
The economics of treating chronic hepatitis B in Asia. Hepatol Int (2008) 1.04
Genetic alterations in the tyrosine kinase transcriptome of human cancer cell lines. Cancer Res (2007) 1.04
Chronic hepatitis B: whom to treat and for how long? Propositions, challenges, and future directions. Hepatol Int (2010) 1.03
Characterization of viral proteins encoded by the SARS-coronavirus genome. Antiviral Res (2005) 1.01
Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. Cancer Treat Rev (2012) 0.97
Rac1 GTPase is activated by hepatitis B virus replication--involvement of HBX. Biochim Biophys Acta (2007) 0.97
Characterization of a unique group-specific protein (U122) of the severe acute respiratory syndrome coronavirus. J Virol (2004) 0.96
Over-expression of severe acute respiratory syndrome coronavirus 3b protein induces both apoptosis and necrosis in Vero E6 cells. Virus Res (2006) 0.95
Prevalence and clinical associations of posttransplant fatty liver disease. Liver Int (2007) 0.95
Molecular and functional characterization of drug-metabolizing enzymes and transporter expression in the novel spontaneously immortalized human hepatocyte line HC-04. Toxicol In Vitro (2007) 0.94
Comparison of the cytotoxicity of the nitroaromatic drug flutamide to its cyano analogue in the hepatocyte cell line TAMH: evidence for complex I inhibition and mitochondrial dysfunction using toxicogenomic screening. Chem Res Toxicol (2007) 0.94
Nanomaterial scaffolds for stem cell proliferation and differentiation in tissue engineering. Biotechnol Adv (2012) 0.93
2-D DIGE profiling of hepatocellular carcinoma tissues identified isoforms of far upstream binding protein (FUBP) as novel candidates in liver carcinogenesis. Proteomics (2008) 0.93
Proteomic approach identifies HSP27 as an interacting partner of the hepatitis C virus NS5A protein. Biochem Biophys Res Commun (2004) 0.93
Population pharmacokinetics of tacrolimus in whole blood and plasma in asian liver transplant patients. Clin Pharmacokinet (2006) 0.93
Severe acute respiratory syndrome coronavirus protein 7a interacts with hSGT. Biochem Biophys Res Commun (2006) 0.92
Mobilizing monocytes to cross-present circulating viral antigen in chronic infection. J Clin Invest (2013) 0.91
CD81 engineered with endocytotic signals mediates HCV cell entry: implications for receptor usage by HCV in vivo. Virology (2003) 0.91
The critical role of calpain versus caspase activation in excitotoxic injury induced by nitric oxide. J Neurochem (2005) 0.91
Prophylactic strategies for hepatitis B patients undergoing liver transplant: a cost-effectiveness analysis. Liver Transpl (2006) 0.90
Public misperceptions about transmission of hepatitis B virus in Singapore. Ann Acad Med Singapore (2007) 0.89
Histone H4 histidine kinase displays the expression pattern of a liver oncodevelopmental marker. Carcinogenesis (2004) 0.89
Hepatitis C virus non-structural protein NS3 interacts with LMP7, a component of the immunoproteasome, and affects its proteasome activity. Biochem J (2004) 0.89
Complexity and health coaching: synergies in nursing. Nurs Res Pract (2013) 0.89
Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research. PLoS One (2013) 0.89
Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. Cancer Chemother Pharmacol (2013) 0.89
Recovery of locked-in syndrome following liver transplantation with calcineurin inhibitor cessation and supportive treatment. Am J Case Rep (2013) 0.88
Understanding the accessory viral proteins unique to the severe acute respiratory syndrome (SARS) coronavirus. Antiviral Res (2006) 0.88
Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. Breast Cancer Res Treat (2012) 0.88
Proteomic identification of down-regulation of oncoprotein DJ-1 and proteasome activator subunit 1 in hepatitis B virus-infected well-differentiated hepatocellular carcinoma. Int J Oncol (2007) 0.88
An investigation of the bioactivation potential and metabolism profile of Zebrafish versus human. J Biomol Screen (2012) 0.87
Increased viral quasispecies evolution in HBeAg seroconverter patients treated with oral nucleoside therapy. J Hepatol (2012) 0.87
Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. Expert Opin Drug Saf (2013) 0.87
The kinetics of p53 activation versus cyclin E accumulation underlies the relationship between the spindle-assembly checkpoint and the postmitotic checkpoint. J Biol Chem (2008) 0.87
Polo-like kinase 1, a new therapeutic target in hepatocellular carcinoma. World J Gastroenterol (2012) 0.86
C/EBPalpha is up-regulated in a subset of hepatocellular carcinomas and plays a role in cell growth and proliferation. Gastroenterology (2010) 0.86
A novel cell-based binding assay system reconstituting interaction between SARS-CoV S protein and its cellular receptor. J Virol Methods (2005) 0.86
Rapid determination of vertebral fat fraction over a large range of vertebral bodies. J Med Imaging Radiat Oncol (2013) 0.85
Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. Expert Opin Drug Metab Toxicol (2014) 0.85
Understanding human immunodeficiency virus type 1 and hepatitis C virus coinfection. Curr HIV Res (2006) 0.85
Regulation of cell death during infection by the severe acute respiratory syndrome coronavirus and other coronaviruses. Cell Microbiol (2007) 0.85
Hepatitis B pregenomic RNA splicing--the products, the regulatory mechanisms and its biological significance. Virus Res (2008) 0.84
Investigating the role of nucleoside transporters in the resistance of colorectal cancer to 5-fluorouracil therapy. Cancer Chemother Pharmacol (2012) 0.83
Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. Br J Clin Pharmacol (2015) 0.83
Inducible system in human hepatoma cell lines for hepatitis C virus production. Virology (2002) 0.83
The severe acute respiratory syndrome coronavirus 3a protein up-regulates expression of fibrinogen in lung epithelial cells. J Virol (2005) 0.83
The p7 protein of the hepatitis C virus induces cell death differently from the influenza A virus viroporin M2. Virus Res (2012) 0.83
Cholangiocarcinoma: has there been any progress? Can J Gastroenterol (2010) 0.82
Enhanced cytotoxicity to cancer cells by mitochondria-targeting MWCNTs containing platinum(IV) prodrug of cisplatin. Biomaterials (2013) 0.82
BAsE-Seq: a method for obtaining long viral haplotypes from short sequence reads. Genome Biol (2014) 0.82
Diagnostic yield of upper endoscopy in Asian patients presenting with dyspepsia. Gastrointest Endosc (2002) 0.82
Ultrasound biomicroscopy of the anterior segment of the enucleated chicken eye during accommodation. Ophthalmic Physiol Opt (2002) 0.81